tbuckley/cabot-search huggingface dataset:
P2.10-02 Smoking Habit in Lung Cancer in Spain
Authors: E. Carcereny, F. Franco, D. Rodriguez-Abreu, R. Lopez Castro, R. De Las Penas, M. Guirado, C. Camps, J. Bosch-Barrera, R. Garcia Campelo, A.L. Ortega, J.L. Gonzalez-Larriba, G. Huidobro, M. Domine, B. Massuti, M.a. Sala, R. Bernabe, J. Oramas, E. Del Barco, J. De Castro Carpeno, A. Padilla, D. Aguiar, S. Cerezo, R. Blanco, E. Cuadrado Albite, G. Benitez, M. Domenech, M. Provencio
Journal: Journal of Thoracic Oncology (2019)
Confronting Bias and Discrimination in Health Care—When Silence Is Not Golden
Authors: Lisa A. Cooper, Mary Catherine Beach, David R. Williams
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Expression of HIF1a and HIF2a in bone metastatic clear cell renal cell cancer and use as prognostic markers.
Authors: Jozsef Timar, Attila Marcell Szasz, Magdolna Kardos, Annamaria Tokes, Janina Kulka, Miklos Szendroi, Attila Szendroi
Journal: Journal of Clinical Oncology (2013)

e15523 Background: Bone metastasis is a frequent complication of ccRCC and predictors of this type of progression are scanty. The aim of this study was to analyse HIF and HIF regulated gene expressions in bone metastatic ccRCC. Methods: A pre-target therapy era cohort of 125 ccRCC patients with &lt;100 month follow-up period have been collected with paraffin embedded primary tumors. 65 patients developed bone metastasis where 45 metastases were available for analysis. RNA was isolated from FFPE tissues and gene expression of HIF1A, HIF2A as well as HIF-regulated genes GLUT1, LDH5, GAPDH, CAIX, VEGF, VEGFR2 and EPOR were measured by RT-PCR using B2M as control. Protein product of these genes was measured on TMA arrays using standardized immunohistochemistry and an image analysis program (Mirax Viewer, 3DHistech). Results: Expression of HIF1A and HIF2A was significantly increased in bone metastatic primary ccRCC tumor tissues both at mRNA and protein levels. Significant upregulation of 3 out of 7 HIF-regulated genes (VEGFR2, EPOR and LDH5) in the primary tumor tissues of bone metastatic ccRCC was proved at mRNA levels and confirmed at protein level for VEGFR2 as well. In bone metastatic tissues a significant overexpression of HIF2A and VEGF mRNA was also detected compared to the primary site. Prognostic power of the protein expression in primary tumor was found for HIF1A (p= .001), HIF2A (p = .041), and VEGFR2 (p = .001) (confirmed at mRNA levels as well) for overall survival at time of surgical removal of primary renal tumor using Kaplan-Meier method and log-rank statistics. To further test the power of HIF1A and HIF2A as prognostic factors we have performed multivariate analysis considering available clinicopathological variables (gender, Fuhrman grade, stage) and found that HIF2A protein level outperformed all other factors in the model. Conclusions: These data indicate that HIF genes are overexpressed in bone metastatic ccRCC among which HIF2A expression at mRNA and protein levels can be used as a strong independent prognostic marker.
EP1.03-02 Frequency of Microsatellite Instability in Patients with Primary Non Small Lung Cancer in a Single Institution from Colombia
Authors: L. Pino, M. Mendoza, G. Saavedra, J. Lozano, C. Echevarria, J. Pino, F. Canro, M. Botero
Journal: Journal of Thoracic Oncology (2019)
A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia
Authors: S. Kunivayalil, A. Jain, C. Satheesh, S. Tejinder, K. Lakshmaiah, T. M. Suresh, D. Lokanatha, G. Babu
Journal: Journal of Clinical Oncology (2009)

e18005 Background: Prophylactic treatment with recombinant human granulocyte colony stimulating factor (rhGCSF) is used to decrease the severity and duration of neutropenia in patients receiving myelosupressive chemotherapy. It can be used during induction and consolidation chemotherapy in acute myeloid leukemia (AML). Mechanism of action of pegylated GCSF is the same as filgrastim except for delayed clearance. Few studies addressed the use of pegylated filgrasim in AML. Methods: After 24 hours of consolidation chemotherapy, 8 patients in the study arm received single dose of subcutaneous 6 mg pegfilgrastim. The control group received daily filgrastim at a dose of 5 microgram per kg.until absolute neutroophil count of 2 ×10 9 cells/μL for 2 consecutive days. The neutrophil recovery time, febrile neutropenia and its duration, duration of hospitalization and safety profiles were compared. Results: There were 20 episodes of pegfilgrastim administration. The median age was 41 years in pegfilgrastim arm and 39 years in filgrastim arm. Medium time to neutrophil recovery was 14 days for pegfilgrastim arm and 17 days for filgrastim arm. In the pegfilgrastim arm 12 (60%) episodes of febrile neutropenia occurred compared to 11 (55%) in filgrastim arm. The median duration of febrile neutropenia was 3 days in pegfilgrastim arm versus 4 days in filgrastim arm. The median duration of hospitalization was 15 days in pegfilgrastim arm and 18 days in filgrastim arm. Safety profile and complete remission status did not differ between the two groups. Conclusions: The present study showed favorable profile of pegfilgrastim for netrophil recovery, duration of neutropenia and hospital stay. There was no difference with regard to safety or response to treatment. No significant financial relationships to disclose.
An over-the-scope clip placed for large colonic perforation can be complicated by delayed bleeding despite its known hemostatic mechanical effect
Authors: Armelle Schoch, Gaspard Bertrand, Jérôme Rivory, Myrtille Fouche, Hugo Tête, Julie Perinel, Mathieu Pioche
Journal: Endoscopy (2019)

The efficacy and safety of the over-the-scope clip (OTSC) to manage acute gastrointestinal defects have been demonstrated for several years [1]. Data have shown a technical success rate of almost 100 % [2], with very good safety [3]. The most common complication after the use of an OTSC for acute gastrointestinal defects is peritonitis, which occurs when leaks remain [4]. We present a case of delayed bleeding after the closure of an iatrogenic colonic perforation with an OTSC ([Video 1]).
OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data
Authors: E. Dudnik, M. Moskovitz, A. Agbarya, T. Kuznetsov, T. Shochat, D. Urban, M. Wollner, A. Zer, O. Rotem, N. Peled, J. Bar
Journal: Journal of Thoracic Oncology (2019)
P1.16-17 Getting to Know Our Weapons Better. Analyze from Real Life Data from León, Spain
Authors: L.F. Sánchez-Cousido, M. Rojas Piedra, M. López Flores, I. Delgado Sillero, A. López González, C. Castañón, B. Nieto Mangudo, M. Pedraza, L. De Sande, S. Medina, Á. Rodriguez, A. García-Palomo, P. Diz Tain
Journal: Journal of Thoracic Oncology (2019)
MA03.03 CEA and CYFRA 21-1 as Prognostic Biomarkers of Benefit from Nivolumab and as a Tool in Treatment Monitoring in Advanced NSCLC
Authors: F.G. Dall'Olio, F. Abbati, F. Facchinetti, F. Gelsomino, B. Melotti, M. Massucci, S. Buti, M. Veneziani, M. Tiseo, A. Ardizzoni
Journal: Journal of Thoracic Oncology (2019)
P1.12-20 Surgical Resection Versus Stereotactic Body Radiation Therapy for T1-2 N0 Typical Bronchopulmonary Carcinoid Tumors
Authors: R. Wegner, V. Verma, S. Abel, S. Hasan, B. Weksler, A. Colonias
Journal: Journal of Thoracic Oncology (2019)
EP1.16-43 Combined Prognostic Value of CYFRA 21-1 and CEA in Overall Survival of Patients with III-IV Clinical Stage NSCLC
Authors: C.J. Flores, A. Aguilar, L. Mas, D. Enriquez, J.M. Gutierrez, L. Schwarz, C. Vallejos
Journal: Journal of Thoracic Oncology (2019)
EP1.14-32 Pattern of EGFR Mutations and Response to First Generation EGFR TKIs in Patients of Metastatic Lung Cancer at a Tertiary Care Centre in India
Authors: S. Saldanha, L. D, L. Jacob, S. Babu, L. N, R. H, R. Lakkavalli, A. Thottian
Journal: Journal of Thoracic Oncology (2019)
P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation
Authors: P. Bironzo, D. Pignataro, M. Audisio, M. Tagliamento, C. Paratore, F. Tabbò, M. Bungaro, C. Zichi, M. De Filippis, S. Rapetti, V. Cetoretta, S. Carnio, A. Mariniello, L. Buffoni, G. Lacidogna, M. Di Maio, S. Novello
Journal: Journal of Thoracic Oncology (2019)
P1.11-06 Expanding Criteria for Lung Cancer Screening Reduces Gender Disparity
Authors: M. Pasquinelli, K. Kovitz, M. Durham, J. Zacny, Z. Deliu, K. Rygalski, L. Liu, M. Koshy, R. Winn, L. Feldman
Journal: Journal of Thoracic Oncology (2019)
The Effect of the CASP8 -6526N Del Promoter Polymorphism on Outcome in T-Cell Depleted Unrelated Donor Haemopoetic Stem Cell Transplants (HSCT)
Authors: Suchitra Krishnamurthy, Bronwen E. Shaw, J. L Byrne, C. Seedhouse, Neema P Mayor, A. J Madrigal, Nigel H. Russell
Journal: Blood (2008)
P1.16-33 From a Systematic Review to Real World Evidence: Integrating Gender as a Clinical Risk Factor in NSCLC
Authors: N. Alsaadoun, K. Kopciuk, D. Hao, F. Hao, A. Elegbede, A. Gibson, M. Dean, R. Tudor, G. Bebb
Journal: Journal of Thoracic Oncology (2019)
Adding chimeric antigen receptor–induced killer cells to the medical oncology shelf
Authors: Brigett D. Brandjes, Marco L. Davila
Journal: Journal of Clinical Investigation (2019)

With the approval of CD19-targeted chimeric antigen receptor (CAR) T cells for the treatment of B cell malignancies, clinicians have gained valuable insights into the power and challenges of cellular therapies. In this issue of the JCI, Maluski et al. showed that a CAR containing a CD28 costimulatory domain drives progeny differentiation to resemble that of NK cells, which have the potential for an off-the-shelf cell therapy. These CAR-induced killer (CARiK) cells displayed potent antitumor function and killed across the MHC barrier in vivo. After performing in vitro and in vivo mouse studies, the authors also successfully differentiated human umbilical cord blood-derived progenitor cells into CARiK cells. These unique cells may address some of the current challenges associated with first-generation CARs, such as prolonged production that requires patients to wait weeks for infusion. We believe this innovative progenitor gene-engineered lymphoid system has the potential for clinical translation.
MA24.11 A Project to Control Passive Smoking by Lung Cancer Patients "Don't Smoke Near Me! Don't Be Like Me!"
Authors: K. Hasegawa, H. Saito, F. Miyake, C. Nakamura, Y. Tanaka, T. Ito, S. Inaba, C. Endo, K. Onishi, M. Onishi, N. Kishimoto, Y. Komatsu, I. Tanaka, M. Tanaka, T. Hatsuda
Journal: Journal of Thoracic Oncology (2019)
EP1.16-21 Frequencies and Prognosis of Non-Small Cell Lung Cancers Complicated with Synchronous/Metachronous Multiple Primary Cancers
Authors: T. Honda, R. Ochiai, T. Haruyama, M. Ishihara, T. Sakamoto, S. Tanzawa, S. Ota, Y. Ichikawa, K. Watanabe, N. Seki
Journal: Journal of Thoracic Oncology (2019)
Balloon-assisted endoscopic extraction of a lamp bulb stuck in the rectosigmoid junction: an inspiration from ERCP
Authors: Zhe Feng, Zi-ming Liu, Lian-song Ye, Wen-juan Yang, Lin-jie Guo, Jing Li, Bing Hu
Journal: Endoscopy (2019)

A 35-year-old man was referred to our hospital owing to insertion of a lamp bulb into his anus 5 hours earlier. The patient’s abdomen was soft and not distensible. An abdominal radiograph showed a spherical opaque foreign body at the junction of the rectum and sigmoid, without any signs of perforation. Proctosigmoidoscopy found a black spherical foreign body (5.0 cm in transverse diameter) at about 15 cm from the anus ([Fig. 1 a]), which was wrapped with black tape and whose neck pointed to the oral side. Several attempts were made to remove it with a snare grasping the neck of the bulb ([Fig. 1 b]). However, the bulb rotated with endoscopic extraction and could not be passed through the acute angle of the rectosigmoid junction. Subsequently, a balloon was delivered over the bulb along a guidewire ([Fig. 1 c]). After inflation of the balloon, the snare and the balloon were pulled outward at the same time ([Fig. 1 d]; [Video 1]). Finally, the bulb was extracted successfully with withdrawal of the scope ([Fig. 2]). There were no additional injuries, and the patient was discharged uneventfully the same day.
EP1.06-11 Advanced Malignant Pleural Mesothelioma: A Single Institution Experience
Authors: L. Gutiérrez Sainz, P. Cruz, S. Martínez Recio, I. Esteban, F. Arias Lotto, D. Viñal, J. Villamayor, D. Sanchez Cabrero, O. Higuera, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)
Core 1–derived mucin-type O-glycosylation protects against spontaneous gastritis and gastric cancer
Authors: Fei Liu, Jianxin Fu, Kirk Bergstrom, Xindi Shan, J. Michael McDaniel, Samuel McGee, Xia Bai, Weichang Chen, Lijun Xia
Journal: The Journal of Experimental Medicine (2019)

Core 1-derived mucin-type O-glycans (O-glycans) are a major component of gastric mucus with an unclear role. To address this, we generated mice lacking gastric epithelial O-glycans (GEC C1galt1-/-). GEC C1galt1-/- mice exhibited spontaneous gastritis that progressed to adenocarcinoma with ∼80% penetrance by 1 yr. GEC C1galt1-/- gastric epithelium exhibited defective expression of a major mucus forming O-glycoprotein Muc5AC relative to WT controls, which was associated with impaired gastric acid homeostasis. Inflammation and tumorigenesis in GEC C1galt1-/- stomach were concurrent with activation of caspases 1 and 11 (Casp1/11)-dependent inflammasome. GEC C1galt1-/- mice genetically lacking Casp1/11 had reduced gastritis and gastric cancer progression. Notably, expression of Tn antigen, a truncated form of O-glycan, and CASP1 activation was associated with tumor progression in gastric cancer patients. These results reveal a critical role of O-glycosylation in gastric homeostasis and the protection of the gastric mucosa from Casp1-mediated gastric inflammation and cancer.
Antihypertensive Medication Use in Older Adults at Risk for Hip Fracture—Reply
Authors: Sarah D. Berry, Douglas P. Kiel, Cathleen Colón-Emeric
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma
Authors: Deirdre O’Mahony, John E Janik, Jorge A. Carrasquillo, Pamela Seam, Joseph A Fiorillo, Donn Stewart, Chang H Paik, Suzanne Fioravanti, Millie Whatley, Stefania Pittaluga, Martin W Brechbiel, John C Morris, Thomas A Waldmann
Journal: Blood (2008)
MA01.03 Interim Safety Analysis of the Phase IB Trial of SBRT to All Sites of Oligometastatic NSCLC Combined with Durvalumab and Tremelimumab
Authors: T. Leal, J. Lang, Z. Morris, J. Eickhoff, A. Traynor, T. Campbell, A. Baschnagel, M. Bassetti
Journal: Journal of Thoracic Oncology (2019)
P1.01-45 A NGS-Based ctDNA Test to Monitor Disease Progression and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer
Authors: J. Jen, J. Jang, J. Zhang, A. Tang, K. Pierson, A. Schrandt, H. Xie, P. Yang, S. Mandreka, A. Mansfield
Journal: Journal of Thoracic Oncology (2019)
P1.03-12 Preclinical Validation of an Epigenetic Panel of Seven miRNAs at Early Stages NSCLC Patients and Its Prognostic Implications
Authors: D. Sanchez Cabrero, P. Cruz, O. Pernia, O. Vera, I. Esteban, R. Rosas, J. Jimenez, I. Losantos, J. De Castro Carpeno, I. Ibañez
Journal: Journal of Thoracic Oncology (2019)
P1.13-04 Impact of the Presence and Proportion of GGO on Survival and Pathological Characteristics in Clinical Stage I Lung Adenocarcinoma
Authors: S. Katsumata, K. Aokage, G. Ishii, S. Nakasone, T. Miyoshi, K. Tane, M. Tsuboi
Journal: Journal of Thoracic Oncology (2019)
EP1.14-34 Advanced NSCLC Treated with Gefitinib or Erlotinib for Five Years or Longer - Updated Data from the Retrospective Slovakian Study
Authors: P. Berzinec, P. Kasan, J. Mazal, I. Andrasina, A. Cipkova, G. Chowaniecova, M. Martak, M. Urda, M. Vesela, I. Jancokova, I. Kuliskova, L. Plank
Journal: Journal of Thoracic Oncology (2019)
P2.03-31 Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Authors: J. Becker, Y. Gao, M. Soucheray, I. Pulido, E. Kikuchi, M. Rodríguez, R. Gandhi, A. Lafuente-Sánchis, M. Aupi, J. Alcacer Fernandez-Coronado, P. Martín, A. Cremades, J. Galbis-Caravajal, J. Alcacer, C. Christensen, P. Simms, A. Hess, H. Asahina, M. Kahle, F. Al-Shahrour, J. Borgia, A. Lahoz, A. Insa, O. Juan, P. Jänne, K. Wong, J. Carretero, T. Shimamura
Journal: Journal of Thoracic Oncology (2019)
P1.03-42 Angiotensin System Inhibitors Improve Survival in Stage IIIA NSCLC and Show Anti-Tumor Effect in Combination with Chemotherapy in a Model of NSCLC
Authors: H. Tang, M. Sojoodi, S. Li, D. Erstad, S. Ghoshal, G. Arora, E. Abston, K. Tanabe, B. Fuchs, M. Lanuti
Journal: Journal of Thoracic Oncology (2019)
EP1.03-17 Outcomes of Molecular Characteristics in Chinese BAP1-Mutant Non-Small Cell Lung Cancer Patients
Authors: H. Ke, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer
Authors: A. Reuben, J. Zhang, R. Gittelman, S. Chiou, J. Li, J. Fujimoto, C. Behrens, F. Kheradmand, C. Chow, C. Bernatchez, A.K. Eterovic, S. Benzeno, M. Vignali, X. Xifeng Wu, Y. Ye, T. Cascone, R. Herbst, S. Swisher, H. Kadara, C. Moran, J. Zhang, P. Scheet, A. Vaporciyan, B. Sepesi, D. Gibbons, H. Robins, P. Hwu, J. Heymach, P. Sharma, J. Allison, J. Lee, M. Davis, I. Wistuba, P.A. Futreal, J. Zhang
Journal: Journal of Thoracic Oncology (2019)
EUGENIC STERILIZATION IN CALIFORNIA
Authors: Paul Popenoe
Journal: American Journal of Psychiatry (1930)

I. A group of 838 patients in the private practice of a psychiatrist on the Pacific Coast is found to come from homes above the average of the state's population in socio-economic status, and much above the average of the patients sterilized in California state hospitals for mental disease. 2. This is selective and is not to be explained as showing that mental diseases occur more frequently in the intellectually superior part of the population. 3. The private patients are rather younger than an institutional population, and are at ages when marriage and childbirth are likely. 4. Significant differences of age and marriage rate are found between patients with various types of mental diseases. 5. Women outnumber men two to one in the classification of manic-depressive psychoses, but this is not believed to represent a genetic difference in the etiology of the disease. 6. When age is taken into account the private patients are found to have a high marriage rate. 7. The divorce rate is much higher in patients with mental disease than it is in the population as a whole. 8. The divorcees apparently constitute a particularly unstable group which marries early and divorces soon after marriage. 9. There is in this group no tendency for men of higher socioeconomic status to marry at later ages. 10. Those who marry late are about as likely to have large families as those who marry early. This points to the widespread use of contraceptive measures in this group, at least among those who marry early. II. The number of living children in the completed family of either male or female patients is three. This is enough to perpetuate the group, and is higher than the size of family in most groups of American college graduates. 12. The relation between size of family and socio-economic status of parents is about the same in this group as in normal groups and other abnormal groups that have been studied. 13. Although dementia præcox patients have a diminished marriageability, the fecundity of those who do marry is relatively high. 14. It is concluded that the existence of a degree of mental disease serious enough to cause the individual to consult a psychiatrist has not tended to reduce the frequency of marriage or the size of family, as compared with the non-psychopathic population of similar age and socio-economic status. 15. If marriage and parenthood are less desirable among psychopaths than in the healthier part of the population, it is evident that further steps, voluntary or compulsory, are required among psychopaths.
P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
Authors: H. Wakelee, K. Reckamp, T. Leal, A. Chiappori, S. Waqar, K. Zeman, J. Neal, C. Liang, K. Harrow, A. Holzhausen, J. Zhou, G. Selvaggi, L. Horn
Journal: Journal of Thoracic Oncology (2019)
OA07.06 Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial
Authors: J. Roth, M. Trivedi, S. Gray, D. Patrick, W. Burke, D. Delaney, K. Watabayashi, P. Litwin, P. Shah, K. Crew, M. Yee, M. Redman, V. Papadimitrakopoulou, K. Kelly, D. Gandara, D. Hershman, S. Ramsey
Journal: Journal of Thoracic Oncology (2019)
EP1.09-21 Sarcomatoid Carcinoma of the Lung. Analysis of the Tumor Immune-Microenvironment and Survival of a Case Series
Authors: A. Koumarianou, A. Liakea, E. Tsagari, E. Kefalidi, J. Duran, T. Raptakis, P. Foukas, P. Tomos
Journal: Journal of Thoracic Oncology (2019)
EP1.10-04 Characteristics of Smoker Patients with Lung Cancer in the Lung Cancer
Authors: J. Rauseo López, J. González Ruiz, M. Hernández Mezquita, R. Cordovilla Pérez, J. Cascón Hernández, V. Guevara Velázquez, M. Rosales Dedios, M. Bartol Sánchez, A. Pascual Rodriguez, M. Barrueco Ferrero
Journal: Journal of Thoracic Oncology (2019)